NIHR Applied Research Collaboration East Midlands, Leicester Diabetes Research Centre, Leicester, UK.
Leicester Kidney Lifestyle Team, Department of Health Sciences, University of Leicester, Leicester, UK.
J Cachexia Sarcopenia Muscle. 2022 Oct;13(5):2426-2435. doi: 10.1002/jcsm.13047. Epub 2022 Jul 19.
Frailty is characterized by the loss of biological reserves and vulnerability to adverse outcomes. In individuals with chronic kidney disease (CKD), numerous pathophysiological factors may be responsible for frailty development including inflammation, physical inactivity, reduced energy intake, and metabolic acidosis. Given that both CKD and frailty incur a significant healthcare burden, it is important to understand the relationship of CKD and frailty in real-world routine clinical practice, and how simple frailty assessment methods (e.g. frailty indexes) may be useful. We investigated the risk of frailty development in CKD and the impact of frailty status on mortality and end-stage kidney disease (ESKD).
A retrospective cohort study using primary care records from the Clinical Practice Research Datalink linked to Hospital Episode Statistics and the UK Office for National Statistics was undertaken in 819 893 participants aged ≥40 years, of which 140 674 had CKD. Frailty was defined using an electronic frailty index, generated electronically from primary care records. Cox proportional hazard and flexible parametric survival models were used to investigate the risk of developing frailty and the effect of frailty on risk of all-cause and cardiovascular mortality, and ESKD.
The mean age of those with CKD was 77.5 (SD 9.7) years [61.0 (SD 12.1) years in no-CKD group]; 62.0% of the CKD group were female (compared with 53.3% in no-CKD group). The mean estimated glomerular filtration rate of those with CKD was 46.1 (SD 9.9) mL/min/1.73 m . The majority of those with CKD (75.3%) were frail [vs. 45.4% in those without CKD (no-CKD)]. Over 3 years (median), 69.5% of those with CKD developed frailty. Compared with no-CKD, those with CKD had increased rates of developing mild (hazard ratio: 1.02; 95% confidence interval: 1.01-1.04), moderate (1.30; 1.26-1.34), and severe (1.50; 1.37-1.65) frailty. Mild (1.22; 1.19-1.24), moderate (1.60; 1.56-1.63), and severe (2.16; 2.11-2.22) frailty was associated with increased rates of all-cause and cardiovascular-related mortality (mild 1.35; 1.31-1.39; moderate 1.96; 1.90-2.02; and severe 2.91; 2.81-3.02). All stages of frailty significantly increased ESKD rates.
Frailty is highly prevalent and associated with adverse outcomes in people with CKD, including mortality and risk of ESKD. Preventative interventions should be initiated to mitigate the development of frailty. The use of a simple frailty index, generated electronically from health records, can predict outcomes and may aid prioritization for management of people with frailty.
衰弱的特征是生物储备的丧失和对不良后果的易感性。在患有慢性肾脏病(CKD)的个体中,许多病理生理因素可能导致衰弱的发展,包括炎症、身体活动减少、能量摄入减少和代谢性酸中毒。鉴于 CKD 和衰弱都会给医疗保健带来巨大负担,了解 CKD 与衰弱在真实世界常规临床实践中的关系,以及简单的衰弱评估方法(例如衰弱指数)如何可能有用,这一点非常重要。我们研究了 CKD 患者衰弱发展的风险,以及衰弱状态对死亡率和终末期肾病(ESKD)的影响。
我们使用来自临床实践研究数据链接(与医院事件统计数据和英国国家统计局相关联)的初级保健记录,对 819893 名年龄≥40 岁的参与者进行了回顾性队列研究,其中 140674 名患有 CKD。使用电子衰弱指数从初级保健记录中电子生成来定义衰弱。使用 Cox 比例风险和灵活参数生存模型来研究发展衰弱的风险,以及衰弱对全因和心血管死亡率以及 ESKD 的影响。
患有 CKD 者的平均年龄为 77.5(SD 9.7)岁[无 CKD 组为 61.0(SD 12.1)岁];62.0%的 CKD 组为女性(无 CKD 组为 53.3%)。患有 CKD 者的估计肾小球滤过率平均值为 46.1(SD 9.9)mL/min/1.73m 。大多数患有 CKD 的患者(75.3%)衰弱[而无 CKD 的患者(无 CKD)为 45.4%]。在 3 年(中位数)内,69.5%的 CKD 患者发展为衰弱。与无 CKD 相比,CKD 患者发展轻度(风险比:1.02;95%置信区间:1.01-1.04)、中度(1.30;1.26-1.34)和重度(1.50;1.37-1.65)衰弱的速度更快。轻度(1.22;1.19-1.24)、中度(1.60;1.56-1.63)和重度(2.16;2.11-2.22)衰弱与全因和心血管相关死亡率增加有关(轻度 1.35;1.31-1.39;中度 1.96;1.90-2.02;重度 2.91;2.81-3.02)。所有衰弱阶段均显著增加了 ESKD 发生率。
衰弱在患有 CKD 的人群中非常普遍,与不良后果相关,包括死亡率和 ESKD 风险。应启动预防干预措施来减轻衰弱的发展。使用从健康记录中电子生成的简单衰弱指数可以预测结果,并可能有助于对衰弱患者进行管理的优先级排序。